Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Sebastian Kobold

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5612-4673; OpenAlex author ID A5050281853, A5123543379. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 12

  1. STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.01.031↗
  2. RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2025-013282↗
  3. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  4. Novel systemic treatment approaches for metastatic pancreatic cancer. Co-author DOI 10.1080/13543784.2022.2037552↗
  5. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s12094-021-02620-x↗
  6. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  7. Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. Co-author DOI 10.1186/s40425-019-0778-7↗
  8. Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. Co-author DOI 10.1186/s40425-019-0830-7↗
  9. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. Last author DOI 10.3389/fimmu.2018.01955↗
  10. Strategies to relieve immunosuppression in pancreatic cancer. Last author DOI 10.2217/imt.15.9↗
  11. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells Co-author DOI 10.1038/cdd.2014.161↗
  12. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Co-author DOI 10.1038/cdd.2014.96↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter Duewell · 7 shared papers, 2014–2026 · strength 0.64
  2. Max M. Schnurr · 6 shared papers, 2014–2026 · strength 0.56
  3. Volker Heinemann · 4 shared papers, 2020–2022 · strength 0.51
  4. Stefan Hubert Boeck · 4 shared papers, 2020–2022 · strength 0.51
  5. Anne Marie Senz · 2 shared papers, 2026 · strength 0.46
  6. Lars M. König · 3 shared papers, 2019–2026 · strength 0.42
  7. Michael Haas · 3 shared papers, 2020–2022 · strength 0.30
  8. Steffen Ormanns · 3 shared papers, 2020–2022 · strength 0.30
  9. Stephan Krüger · 3 shared papers, 2020–2022 · strength 0.30
  10. Jens Werner · 3 shared papers, 2020–2022 · strength 0.30
  11. Christoph Benedikt Westphalen · 3 shared papers, 2020–2022 · strength 0.30
  12. Julia V. Mayerle · 2 shared papers, 2020–2026 · strength 0.30
  13. Philipp Metzger · 3 shared papers, 2019–2021 · strength 0.27
  14. Ignazio Piseddu · 1 shared paper, 2026 · strength 0.21
  15. Ivonne Regel · 1 shared paper, 2026 · strength 0.21
  16. Veit Hornung · 1 shared paper, 2026 · strength 0.21
  17. Klara Dorman · 1 shared paper, 2022 · strength 0.20
  18. Felicitas Rataj · 2 shared papers, 2018–2021 · strength 0.19
  19. Jens Thomas Siveke · 3 shared papers, 2014–2022 · strength 0.19
  20. Annalena Abendroth · 1 shared paper, 2022 · strength 0.11
  21. Andreas Wolfgang Berger · 1 shared paper, 2022 · strength 0.11
  22. Volker Kunzmann · 1 shared paper, 2022 · strength 0.11
  23. Oliver Waidmann · 1 shared paper, 2022 · strength 0.11
  24. Marianne Sinn · 1 shared paper, 2022 · strength 0.11
  25. Thomas Jens Ettrich · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.